Physician profile
John Tung
NPI 1194832311
$2,788.97
in general payments reported to CMS, 2019-2025
17 companies · $668 in 2025
The $668 reported for 2025 was more than what 78% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $280 · 2021: $263 · 2022: $459 · 2023: $461 · 2024: $409 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $681.93 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $669.04 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $307.28 | 2022-2025 | Dupixent |
| Amgen INC. | $185.07 | 2021-2023 | Avsola, Amjevita |
| Mirum Pharmaceuticals, INC. | $175.43 | 2023-2025 | Livmarli |
| Abbott Laboratories | $166.30 | 2023 | |
| Horizon Therapeutics Plc | $140.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $111.43 | 2020 | |
| Alexion Pharmaceuticals, INC. | $98.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.26 | 2021-2025 | Eohilia, Entyvio |
| Merck Sharp & Dohme LLC | $51.98 | 2019 | |
| Abbvie INC. | $29.03 | 2021 | |
| Albireo Pharma, INC. | $27.69 | 2023 | Bylvay |
| Ipsen Biopharmaceuticals, INC | $16.69 | 2024 | Bylvay |
| Celltrion USA INC. | $16.04 | 2025 | Vegzelma |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $14.44 | 2025 | Givlaari |
| Celgene Corporation | $12.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.